Ryosuke Yamaga

Body Mass Index-Related Trends in Adverse Events with Enfortumab Vedotin: Analysis of a Pharmacovigilance Database and Medical Records

Abstract Background Enfortumab vedotin (EV) is an antibody–drug conjugate used to treat advanced urothelial carcinoma. Although EV therapy is effective, adverse events—particularly skin disorders—pose a challenge to optimal treatment. Previous reports suggest that body mass index...